Monday, May 20News and updates from Kashmir

Wuhan Scientists Warns Against New Combined Variation of Corona Virus- ‘NeoCov’

Virologists and scientists from Wuhan have issued a warning which says that a new prototype combination known as ‘NeoCov’ has been found.

‘NeoCov’ which is actually being said to be the combination of MIDDLE EAST RESPIRATORY SYNDROME (MERS-COV Virus) and SARS-COV-2 virus is more dangerous and risky with maximum mortality rates and transmission capacity.

The scientists are identifying it to be first discovered in the outbreaks of middle eastern countries in 2012 and 2015. Later it was categorized to be an infection only to be traced in Bat populations in South Africa. But further research states that it has similar traits like SARS-COV-2 and humans too can be affected with it. It is relatable to Spike Protein, PREDICT-2180-COV which will lead to infection in humans.

Immunologists, virologists, Scientists on Protein Studies are fearful that the mortality rate might reach to 3:1 ratio i.e every one person will succumb to the infection out of three. It will just take only one cell mutation to transmit and spread to the respiratory organ. It is because antibodies or protein molecules cannot be produced by people with respiratory dysfunction or even who are immunized/vaccinated with the same problem. Diabetes or High Blood Sugar level will always act as a strong catalyst for fast expansion.

The specialists are talking about the high risk because the Angiotensin-Converting Enzyme 2 or ACE2 RECEPTOR binding formula is very different than the Corona Virus (SARS-COV-2) Pathogen formation resulting in no production of Antibodies or Protein Molecular Enzymes in people with Respiratory problems and lesser in quantity for otherwise cases.

A brief explanation, causality, and monotype of this new combined MERS-COV+SARS-COV-2= NEOCoV virus was issued by the Russian State Virology and Biotechnology Research Center on Thursday. Further studies in details of accurate nature, preventive measures of the NEOCoV are in progress.

Leave a Reply

Your email address will not be published. Required fields are marked *